INFOPOEMS

Document Sample
INFOPOEMS Powered By Docstoc
					i      n     f     o     p     o      e    m      s

These InfoPOEMs® are selected by JNMA InfoPOEMS Editor Gregory E. Gilbert, MSPH, (Gregory.E.Gilbert@
gmail.com) and Associate InfoPOEMS Editor Amy H. Wahlquist, MS, from www.infopoems.com. InfoPOEMs®
are created by experts who continuously survey medical journals worldwide. They identify and summa-
rize valid and clinically applicable new evidence. For more information or to subscribe to e-mail alerts of
InfoPOEMs®, please visit www.infopoems.com.
    STUDY LEVELS OF EVIDENCE (LOE)                                                            tivitamin component (this study is
    From the Centre for Evidence-Based                Vitamins E and C and                    still ongoing). Complete follow-up
    Medicine, Oxford. For the most up-to-             Selenium Do Not Reduce                  occurred for 98% of men at 8 years.
    date levels of evidence, see www.cebm.
    net/levels_of_evidence.asp)                       Risk of Prostate or Total               Individuals assessing outcomes
                                                      Cancer in Men                           remained masked to treatment
    Therapy/Prevention/Etiology/Harm:                                                         group assignment. Using intention-
    1a: Systematic reviews of randomized              Clinical Question                       to-treat analysis, neither vitamin
         controlled trials                                Do vitamins E and C or sele-        E nor C had any significant effect
    1b: Individual randomized controlled              nium, alone or in combination,          on the incidence of prostate can-
         trials
    1c: All or none randomized controlled
                                                      reduce the risk of prostate cancer or   cer, total cancer, or all-cause mor-
         trials                                       total cancer in men?                    tality. Neither vitamin significantly
    2a: Systematic reviews of cohort studies                                                  reduced the individual incidence of
    2b: Individual cohort study or low-               Bottom Line                             colorectal, lung, bladder, or pancre-
         quality randomized controlled
                                                         In this large, well-designed, ran-   atic cancer. In secondary outcome
    2c: “Outcomes” research, ecological
         studies                                      domized trial, vitamins E and C and     analyses, vitamin E was associated
                                                      selenium, alone or in combination,      with a significantly increased risk
    Diagnosis:                                        did not reduce the risk of prostate     of hemorrhagic stroke. The study
    1a: Systematic review of level-1                  cancer, total cancer, or all-cause      was designed to have a greater than
         diagnostic studies                           mortality. (LOE = 1b)                   80% power to detect a 13% reduc-
    1b: Independent blind comparison
         of an appropriate spectrum
                                                                                              tion in the risk of total cancer. A
         of consecutive patients, all of              Study Design                            related article in the same jour-
         whom have undergone both the                    Randomized controlled trial          nal (Lippman SM, et al. JAMA.
         diagnostic test and the reference
         standard, or a clinical decision rule
                                                      (double-blinded)                        2009;301:39-51) also reported that
         not validated on a second set of                                                     neither selenium nor vitamin E,
         patients                                     Funding                                 alone or together, reduced the risk
    1c: Absolute SpPins and SnNouts                     Industry + govt                       of prostate cancer.
    2a: Systematic review of level >2
    2b: Independent blind or objective
         comparison, study confined
                                                      Allocation                              REFERENCE
                                                         Concealed                            Gaziano JM, Glynn RJ, Christen WG, et al. Vita-
         to a narrow spectrum of study
                                                                                              mins E and C in the prevention of prostate and
         individuals, or a diagnostic clinical
                                                                                              total cancer in men. The Physicians’ Health
         rule not validated in a test set
                                                      Setting                                 Study II randomized controlled trial. JAMA.
                                                         Outpatient (any)                     2009;301:52-62.
    Prognosis:
    1a: Systematic review of inception
         cohort studies                               Synopsis
    1b: Individual inception cohort study         
				
DOCUMENT INFO
Description: A global leader in serving libraries of all types, ProQuest LLC (“ProQuest”) supports the breadth of the information community with innovative discovery solutions that power the business of books and the best in research experience. More than a content provider or aggregator, ProQuest is an information partner, creating indispensable research solutions that connect people and information. Through innovative, user-centered discovery technology, ProQuest offers billions of pages of global content that includes historical newspapers, dissertations, and uniquely relevant resources for researchers of any age and sophistication—including content not likely to be digitized by others.
BUY THIS DOCUMENT NOW PRICE: $6.95 100% MONEY BACK GUARANTEED
PARTNER ProQuest LLC
ProQuest creates specialized information resources and technologies that propel successful research, discovery, and lifelong learning.